Swiss-based Novartis recently announced the discontinuation of the CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients based on the interim analysis from the study.…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.